Angelo Zullo1, Cesare Hassan, Lorenzo Ridola, Vincenzo De Francesco, Luigi Rossi, Silverio Tomao, Dino Vaira, Robert M Genta. 1. *Department of Gastroenterology and Digestive Endoscopy, Nuovo Regina Margherita Hospital ‡Oncology Unit, S. Maria Goretti Hospital, Latina, University of Rome "Sapienza", Rome †Gastroenterology Unit, Riuniti Hospital, Foggia §Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy ∥Miraca Research Institute, Miraca Life Sciences, Irving ¶Departments of Pathology and Medicine (Gastroenterology), University of Texas Southwestern Medical Center, Dallas, TX.
Abstract
AIM: To assess the remission rate of gastric low-grade B-cell mucosa-associated lymphoid tissue lymphoma after an eradication therapy in Helicobacter pylori-negative patients. METHODS: We performed a systematic review with pooled analysis of published studies. Data were analyzed according to: (1) number of H. pylori-negative patients treated with only eradication therapy; (2) number of patients in whom the complete lymphoma remission was achieved; and (3) the method used to exclude H. pylori infection. RESULTS: Overall, 11 studies with 110 patients met the inclusion criteria for this pooled analysis. H. pylori infection was excluded in all studies with at least 3 different diagnostic tests. Eradication therapy achieved a complete lymphoma regression in 17 (15.5%; 95% confidence interval, 8.7-22.2) patients. CONCLUSIONS: Eradication therapy is successful in a small but distinct subgroup of H. pylori-negative patients with low-grade mucosa-associated lymphoid tissue lymphoma. On the basis of the generally indolent behavior of this neoplasia, before resorting to aggressive, costly, and potentially more toxic oncologic therapies, it would seem reasonable to attempt eradication therapy in all patients, irrespective of their H. pylori status.
AIM: To assess the remission rate of gastric low-grade B-cell mucosa-associated lymphoid tissue lymphoma after an eradication therapy in Helicobacter pylori-negative patients. METHODS: We performed a systematic review with pooled analysis of published studies. Data were analyzed according to: (1) number of H. pylori-negative patients treated with only eradication therapy; (2) number of patients in whom the complete lymphoma remission was achieved; and (3) the method used to exclude H. pyloriinfection. RESULTS: Overall, 11 studies with 110 patients met the inclusion criteria for this pooled analysis. H. pyloriinfection was excluded in all studies with at least 3 different diagnostic tests. Eradication therapy achieved a complete lymphoma regression in 17 (15.5%; 95% confidence interval, 8.7-22.2) patients. CONCLUSIONS: Eradication therapy is successful in a small but distinct subgroup of H. pylori-negative patients with low-grade mucosa-associated lymphoid tissue lymphoma. On the basis of the generally indolent behavior of this neoplasia, before resorting to aggressive, costly, and potentially more toxic oncologic therapies, it would seem reasonable to attempt eradication therapy in all patients, irrespective of their H. pylori status.
Authors: Eun Jeong Gong; Ji Yong Ahn; Hwoon-Yong Jung; Hyungchul Park; Young Bo Ko; Hee Kyong Na; Kee Wook Jung; Do Hoon Kim; Jeong Hoon Lee; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim Journal: Gut Liver Date: 2016-09-15 Impact factor: 4.519